Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study

• Celldex Therapeutics Inc (NASDAQ: CLDX) announced interim data from Phase 1b trial of barzolvolimab in chronic spontaneous urticaria (CSU) refractory to antihistamines.

• CSU is characterized by the occurrence of hives or weals for six weeks or longer without identifiable specific triggers or causes.

• Data show that multiple doses of barzolvolimab resulted in dose-dependent decreases in itch and hives, with a mean UAS7 reduction of 66.6% in the 1.5 mg/kg dose group (n=8) at week 12 and 75.1% in 3.0 mg/kg dose group (n=9) at week 8, demonstrating meaningful symptom improvements for patients.

• Complete response was 57.1% for the 1.5 mg/kg dose group and 44.4% for 3.0 mg/kg dose group.

• Barzolvolimab demonstrated a favorable safety profile, supporting Phase 2 clinical development.

• The Phase 1b study is expected to enroll approximately 40 patients with CSU across four cohorts, either alone or in combination with H2-antihistamines and/or leukotriene receptor agonists.

• Price Action: CLDX shares are down 14.95% at $22.93 during the market session on the last check Friday.

See more from Benzinga

• The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

• FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.